Protocol: HLA-DQB1*0301, HLA-DQB1*0501, and HLA-DQA1*0301 and Their Role in Scleroderma- A Systematic Review
Dylan Thibaut, Jared Lehman, Alexis Marquess, Kersten Schroeder
Abstract
Scleroderma remains a debilitating autoimmune condition with immunological linkage to HLA sequences remaining open for further explanation. Through understanding the linkage of specific HLAs to scleroderma, the immunological processes behind the condition can be elucidated. HLA meta-analysis with scleroderma offers a prognostic application to best interpret the odds of scleroderma given a specific HLA. We hope to conduct a meta-analysis to determine how HLA-DQB10301, HLA-DQB10501, and HLA-DQA1*0301 are linked with scleroderma.
Steps
Administrative Information
Title
Protocol: HLA-DQB10301, HLA-DQB10501, and HLA-DQA1*0301 and Their Role in Scleroderma- A Systematic Review
Registration
Registration is via protocols.io
Authors
Dylan Thibaut: Lake Erie College of Osteopathic Medicine - Bradenton, AdventHealth- Sebring, University of Central Florida
ORCID: https://orcid.org/0000-0002-8739-9688
Jared Lehman: Lake Erie College of Osteopathic Medicine - Bradenton, AdventHealth- Sebring
ORCID: https://orcid.org/0000-0001-7524-9175
Alexis Marquess: Lake Erie College of Osteopathic Medicine - Bradenton
ORCID: https://orcid.org/0000-0001-6799-9072
Principle Investigator
Dr. Kersten T Schroeder, PhD: University of Central Florida
Amendments
None
Support
Sources: No financial sources used
Sponsor: Lake Erie College of Osteopathic Medicine- Bradenton
Role of Sponsor: to facilitate ethical research and oversee the research process from start to end
Introduction
Rationale
Scleroderma remains a debilitating autoimmune condition with immunological linkage to HLA sequences remaining open for further explanation. Through understanding the linkage of specific HLAs to scleroderma, the immunological processes behind the condition can be elucidated. In addition, HLA meta-analysis with scleroderma offers a prognostic application to best interpret the odds of scleroderma given a specific HLA.
Objectives
We hope to conduct a meta-analysis to determine how HLA-DQB10301, HLA-DQB10501, and HLA-DQA1*0301 are linked with scleroderma.
Methods
Eligibility criteria
Only studies between 1995 and 2022 are included.
Information sources
Google Scholar and Pubmed will be accessed during the duration of the study to gather data.
Study records
Data management
Data will be collected by two researchers and will be compiled on a document.
Selection process
To be included, articles must: contain odds ratio (or enough data to calculate it), be in English, and must use living human test subjects.
Inadequate information for meta-analysis, studies with flawed design, or meta-analyses on the same HLAs are not included.
Data collection process
Two researchers will individually find and compare studies for inclusion. If in disagreement, researchers will present the study to the PI for the PI to make the final decision on whether to include the information.
Data Items
Data collected will include case numbers, control numbers, associated p values if available, the samples studied, odds ratios, confidence intervals, and the name as well as year of the study examined.
Outcomes and prioritization
HLA-DQB10301, HLA-DQB10501, and HLA-DQA1*0301 will specifically be examined.
Risk of bias in individual studies
The NIH Quality Assessment of case-control studies tool will be used for risk of bias assessment as well as a generated DOI plot.
Data Synthesis
15a: Data will be examined using Revman 5.4 and/or MetaXL as needed.
15b: I^2 will be used as a method of examining heterogeneity.
15c: MetaXL or Revman 5.4 are used if needed for sensitivity analysis.
15d: Quantitative synthesis is appropriate.
Meta-bias and Confidence
Meta-bias and confidence in cumulative evidence
GRADE criteria will be used.
